Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3681291 | 0.93 | C5AR1 (0.46) | C5AR1FFAR4THRATHRBS1PR1 | |
| SCHEMBL3883616 | 0.91 | C5AR1 (0.48) | C5AR1FFAR4THRATHRBS1PR1 | |
| SCHEMBL3888525 | 0.90 | C5AR1 (0.45) | C5AR1FFAR4THRATHRBS1PR1 | |
| SCHEMBL3882832 | 0.89 | C5AR1 (0.46) | C5AR1FFAR4THRATHRBS1PR1 | |
| SCHEMBL3883780 | 0.87 | FFAR4 (0.46) | C5AR1FFAR4THRATHRBS1PR1 | |
| SCHEMBL3675617 | 0.86 | FFAR4 (0.43) | C5AR1FFAR4THRATHRBS1PR1 | |
| SCHEMBL3887159 | 0.85 | FFAR4 (0.44) | C5AR1FFAR4THRATHRBS1PR1 | |
| SCHEMBL3682691 | 0.84 | FFAR4 (0.48) | C5AR1FFAR4THRATHRBS1PR1 | |
| SCHEMBL3682868 | 0.84 | FFAR4 (0.43) | C5AR1FFAR4THRATHRBS1PR1 | |
| SCHEMBL3883274 | 0.84 | FFAR4 (0.55) | C5AR1FFAR4THRATHRBS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1477472-B1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2009-01-14 | — | — | EP | claimed |
| US-6867320-B2 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-15 | — | — | US | claimed |
| EP-1477472-A1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2004-11-17 | — | — | EP | claimed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | claimed |
| EP-1477472-B1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-6867320-B2 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-15 | — | — | US | disclosed |
| EP-1477472-A1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | PTGER1, CYSLTR1, PTGS1 | C5AR1 282/4885FFAR4 115/4885THRA 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.